FGF2 and systemic sclerosis: The main finding of ours is that 3 proteins with angiogenetic and fibrotic processes regulation significance are differentially expressed in preclinical SSc patients according to the future 5-year progression, and namely endostatin, bFGF, and PAF-AHβ.